MIM
STIM icon

MetLife Investment Management’s Neuronetics STIM Stock Holding History

MetLife Investment Management’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,070
Closed -$161K – 2582
2021
Q2 		$161K Buy
+10,070
New +$139K ﹤0.01% 2289

Other funds holding STIM

CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

MetLife Investment Management's STIM Position: Q3 2021 in Review

MetLife Investment Management sold out of Neuronetics (STIM) in Q3 2021, closing a stake of 10,070 shares — an estimated $161K sold.

MetLife Investment Management first reported a position in STIM in Q2 2021 and held it in 1 quarter. The position peaked at $161K in Q2 2021. 97 funds tracked by Wall St. Rank hold STIM as of Q3 2021.

  • MetLife Investment Management reported no remaining Neuronetics position as of Q3 2021 after selling out during the quarter.
  • MetLife Investment Management sold 10,070 Neuronetics shares in Q3 2021, an estimated $161K.
  • MetLife Investment Management first reported a position in Neuronetics in Q2 2021 and held it in 1 quarter.
  • MetLife Investment Management's Neuronetics position peaked at $161K in Q2 2021.
  • 97 funds tracked by Wall St. Rank held Neuronetics as of Q3 2021.

Based on MetLife Investment Management's 13F filing for Q3 2021, filed 15 Nov 2021.